A Castaigne1, A M Duval-Moulin, J L Dubois-Randé
1Service de cardiologie, hôpital Henri-Mondor, Créteil.
Evaluating thrombolytic drugs for myocardial infarction requires assessing benefit-risk. Mortality is the sole definitive measure, as current physiopathological concepts lack validation from therapeutic trials.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science: